Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
Subscribe To Our Newsletter & Stay Updated
